Literature DB >> 29201500

Metabesity and urological cancers.

Ali Atan1.   

Abstract

Metabolic syndrome is one of today's most important health problems. Due to increased prevalence of metabolic syndrome in society, studies done on this topic have increased in number. Although metabolic syndrome was previously considered to be important only for cardiovascular health, it has been learned that with new data, human health is compromised more thoroughly by metabolic syndrome and is also a danger to malignancy. As a result, a new definition in the form of metabesity has been introduced. In this review, available information on metabesity and urological cancers is presented.

Entities:  

Keywords:  Metabolic syndrome; metabesity; prostate cancer; renal cancer

Year:  2017        PMID: 29201500      PMCID: PMC5687200          DOI: 10.5152/tud.2017.66502

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  40 in total

1.  Hypertriglyceridemia as a possible risk factor for prostate cancer.

Authors:  L Wuermli; M Joerger; S Henz; H-P Schmid; W F Riesen; G Thomas; W Krek; T Cerny; S Gillessen
Journal:  Prostate Cancer Prostatic Dis       Date:  2005       Impact factor: 5.554

Review 2.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

3.  Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.

Authors:  Bimal Bhindi; Jennifer Locke; Shabbir M H Alibhai; Girish S Kulkarni; David S Margel; Robert J Hamilton; Antonio Finelli; John Trachtenberg; Alexandre R Zlotta; Ants Toi; Karen M Hersey; Andrew Evans; Theodorus H van der Kwast; Neil E Fleshner
Journal:  Eur Urol       Date:  2014-02-14       Impact factor: 20.096

4.  Association between prostate cancer and serum testosterone levels.

Authors:  Ping L Zhang; Seymour Rosen; Ravindra Veeramachaneni; Jerry Kao; William C DeWolf; Glenn Bubley
Journal:  Prostate       Date:  2002-11-01       Impact factor: 4.104

Review 5.  Meta-analysis of metabolic syndrome and prostate cancer.

Authors:  M Gacci; G I Russo; C De Nunzio; A Sebastianelli; M Salvi; L Vignozzi; A Tubaro; G Morgia; S Serni
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-02-21       Impact factor: 5.554

6.  Components of metabolic syndrome and prognosis of renal cell cancer.

Authors:  Tommi J Eskelinen; Andres Kotsar; Teuvo L J Tammela; Teemu J Murtola
Journal:  Scand J Urol       Date:  2017-07-26       Impact factor: 1.612

Review 7.  Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review.

Authors:  Sherita H Golden; Karen A Robinson; Ian Saldanha; Blair Anton; Paul W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  2009-06       Impact factor: 5.958

8.  Relationship between serum prostate-specific antigen levels and components of metabolic syndrome in healthy men.

Authors:  June Hyun Han; Nak Young Choi; Seong Hak Bang; Oh Jung Kwon; Young Woo Jin; Soon Chul Myung; In Ho Chang; Tae Hyoung Kim; Seung Hyun Ahn
Journal:  Urology       Date:  2008-08-13       Impact factor: 2.649

Review 9.  The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence.

Authors:  Yu-zhu Xiang; Hui Xiong; Zi-lian Cui; Shao-bo Jiang; Qing-hua Xia; Yong Zhao; Guan-bin Li; Xun-bo Jin
Journal:  J Exp Clin Cancer Res       Date:  2013-02-13

Review 10.  Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.

Authors:  Vincenzo Quagliariello; Sabrina Rossetti; Carla Cavaliere; Rossella Di Palo; Elvira Lamantia; Luigi Castaldo; Flavia Nocerino; Gianluca Ametrano; Francesca Cappuccio; Gabriella Malzone; Micaela Montanari; Daniela Vanacore; Francesco Jacopo Romano; Raffaele Piscitelli; Gelsomina Iovane; Maria Filomena Pepe; Massimiliano Berretta; Carmine D'Aniello; Sisto Perdonà; Paolo Muto; Gerardo Botti; Gennaro Ciliberto; Bianca Maria Veneziani; Francesco De Falco; Piera Maiolino; Michele Caraglia; Maurizio Montella; Rosario Vincenzo Iaffaioli; Gaetano Facchini
Journal:  Oncotarget       Date:  2017-05-02
View more
  1 in total

Review 1.  2,4 Dinitrophenol as Medicine.

Authors:  John G Geisler
Journal:  Cells       Date:  2019-03-23       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.